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Summary
 
The precise role of B cells in systemic autoimmunity is incompletely understood. Although B
cells are necessary for expression of disease (Chan, O., and M.J. Shlomchik. 1998. 
 
J. Immunol.
 
160:51–59, and Shlomchik, M.J., M.P. Madaio, D. Ni, M. Trounstine, and D. Huszar. 1994.
 
J. Exp. Med.
 
 180:1295–1306), it is unclear whether autoantibody production, antigen presenta-
tion, and/or other B cell functions are required for the complete pathologic phenotype. To ad-
dress this issue, two experimental approaches were used. In the first, the individual contribu-
tions of circulating antibodies and B cells were analyzed using MRL/MpJ-
 
Fas
 
lpr
 
 (MRL/
 
lpr
 
)
mice that expressed a mutant transgene encoding surface immunoglobulin (Ig), but which did
not permit the secretion of circulating Ig. These mice developed nephritis, characterized by
cellular infiltration within the kidney, indicating that B cells themselves, without soluble au-
toantibody production, exert a pathogenic role. The results indicate that, independent of serum
autoantibody, functional B cells expressing surface Ig are essential for disease expression, either
by serving as antigen-presenting cells for antigen-specific, autoreactive T cells, or by contribut-
ing directly to local inflammation.
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S
 
ystemic lupus erythematosus (SLE) is considered to be
an immune disease in which the deposition of immune
complexes or direct autoantibody deposition leads to the
activation of complement, ligation of FcRs, and subsequent
inflammation (1). Nevertheless, mononuclear infiltrates along
with autoantibodies are usually present in affected tissues,
including vessels, salivary glands, skin, and kidneys (2–10).
In these situations, infiltrating T cells, macrophages, and
other cells reside within destructive lesions (4–6). In partic-
ular, interstitial nephritis (IN)
 
1
 
 is relatively common in
human SLE; and this finding is associated with a poor prog-
nosis (7, 9, 11, 12). These observations raise questions about
the relative roles and connections between humoral and cell-
ular autoimmunity. On the one hand, immune complex for-
mation may lead to cellular recruitment. Alternatively, T cell
infiltration may occur directly through antigen-specific
events involving either macrophages or parenchymal cells.
Deciphering the contributions of these events in tissue injury
has both mechanistic and therapeutic implications.
To develop a better understanding of the role of B cells
during systemic autoimmunity, we created the J
 
H
 
D-MRL/
 
MpJ-
 
Fas
 
lpr
 
 mouse strain, (J
 
H
 
D), a strain of MRL/
 
lpr
 
 that lacks
B cells (13, 14). The MRL/
 
lpr
 
 strain develops a spectrum of
disease manifestations that is quite similar to fulminant hu-
man SLE, including severe nephritis, vasculitis, sialoadenitis,
and skin disease (15). When rendered B cell deficient, these
animals lacked not only the classic immune-deposit manifes-
tations of nephritis, such as glomerulonephritis (GN), but
also failed to develop cellular infiltrates within organs, in-
cluding IN, vasculitis (13), and skin disease (Chan, O.T.M.,
J. McNiff, and M.J. Shlomchik, manuscript in preparation).
Furthermore, the absence of B cells substantially blocked the
accumulation of activated and memory T cells (16).
Although these results clearly define a critical role for a B
cell function(s) in the development of pathogenic lesions,
they do not distinguish the precise roles of autoantibodies
and B cells (i.e., independent from soluble antibodies).
Here, we present a novel system to distinguish these mech-
anisms by developing an MRL/
 
lpr 
 
mouse with B cells but
no circulating antibodies. These animals demonstrate T cell
 
1
 
Abbreviations used in this paper:
 
 dsDNA, double stranded DNA; GN,
glomerulonephritis; IN, interstitial nephritis; mIgM, membrane IgM;
NOD, nonobese diabetic; NP, (4-hydroxy-3-nitro-phenyl) acetyl; Tg,
transgene; Tgic, transgenic. 
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activation, cellular infiltration including vasculitis and IN,
and increased mortality, indicating that autoreactive B cells
promote the development of pathogenic T cells in this dis-
ease. The results support a novel and important role for B
cells in the pathogenesis of systemic autoimmunity.
 
Materials and Methods
 
Transgene Construction.
 
The mIgM construct: a VDJ region
containing the canonical anti-(4-hydroxy-3-nitro-phenyl) acetyl
membrane (NP) V
 
H
 
186.2 was cut from plasmid C
 
m
 
B1-8.24, con-
taining the V region of the hybridoma B1-8 (17), using EcoRI and
XbaI. It was then ligated to an XbaI-EcoRI fragment containing
the IgH intronic enhancer region from plasmid C
 
m
 
19.7.1
 
 
 
(17). The
BglII-XhoI fragment of pICEM-C
 
m
 
 (containing C
 
m
 
1-4, and
membrane and secreted exons) was replaced by the corresponding
region from pSV5-C
 
m
 
m, from which the secreted exon and poly-
adenylation site had been deleted (18). The EcoRI-XhoI fragment
of the resulting plasmid, pICEM-C
 
m
 
m, was then inserted into
pBKS-II. The VDJ-enhancer unit was then excised as an EcoRI
fragment and inserted at the EcoRI site of calf intestinal phosphatase
(CIP)-treated pBKS-C
 
m
 
m; correct orientation was confirmed by
restriction digest. The resulting V
 
H
 
186.2–mIgM construct (termed
mIgM hereon) encodes membrane-bound, but not secreted, IgM
 
a
 
.
The mIgM construct was tested by transfection into the CH1
cell line, which expresses IgM
 
b
 
 using 
 
l
 
 light chain. Although
FACS
 
®
 
 analysis confirmed the presence of NP-binding IgM
 
a
 
 on
transfectants, no IgM
 
a
 
 was detectable by ELISA in culture super-
natant. Transgenic (Tgic) mice resulting from microinjection of
the purified DNA construct were initially identified by Southern
blot analysis.
 
Mice.
 
Mice bearing the mIgM transgene (Tg) were initially
backcrossed with MRL/
 
lpr
 
 mice four times, fixing homozygosity
for 
 
lpr
 
. The resultant Tg-positive mice were then backcrossed to
the J
 
H
 
D/
 
lpr
 
 strain to fix homozygosity of the J
 
H
 
D mutation, a 
 
neo
 
insertion in the J
 
H
 
 locus (fixation occurred after backcross one).
This eliminated the expression of endogenous Ig heavy chains.
All subsequent Tg-positive mice were generated by backcrossing
to the J
 
H
 
D/
 
lpr
 
 strain. Through this breeding strategy, all the Tgic
animals used in this study had 
 
.
 
98.9% MRL genes. The resulting
mIgM.MRL/MpJ-
 
Fas
 
lpr
 
 mice (termed mIgM mice hereon) have
functional B cells that do not secrete appreciable Ig (see below).
All animals used in this study were obtained from our colony at
the Yale University School of Medicine (New Haven, CT) and
were housed under specific pathogen-free conditions. All Tgic
mice and controls analyzed in this study were aged 24 wk or more.
A PCR detecting the rearranged V
 
H
 
186.2 V(D)J segment of the
mIgM Tg was used to identify the Tg-positive mice. The oligo-
nucleotides used for this PCR were V
 
H
 
186.2 5
 
9
 
 (5
 
9
 
-TGCTCTT-
CTTGGCAGCAAC-3
 
9
 
 [5
 
9
 
 primer]) and V
 
H
 
186.2 3
 
9
 
 (5
 
9
 
-TGAGG-
AGACTGTGAGAGTG-3
 
9
 
 [3
 
9
 
 primer]). Amplification conditions
were 94
 
8
 
C for 2 min and 35 cycles of 30 s each at 94
 
8
 
C, 54
 
8
 
C,
and 72
 
8
 
C, followed by a 7-min incubation at 72
 
8
 
C. Homozygos-
ity for 
 
lpr
 
 was detected by PCR as previously described (13).
 
Reagents and Antibodies.
 
The following mAbs were used as
FACS
 
®
 
 reagents in this study: CD19 (1D3-biotin; PharMingen);
B220 (RA3-6B2-FITC); CD4 (H129.19-CyChrome; PharMin-
gen); CD44 (Pgp-1-FITC); CD62L (Mel-14–biotin); and anti–
mouse Fc
 
g
 
 receptor (2.4G2). Streptavidin-conjugated PE (Mo-
lecular Probes) was added as a secondary step for the biotinylated
reagents. Pgp-1, Mel-14, and RA3-6B2 were purified from hy-
bridoma supernatants on protein G columns (Amersham Pharmacia
Biotech) after ammonium sulfate precipitation, and were conju-
gated as described (19). The antibodies were verified by comparison
with commercially available antibodies with the same specificities.
The following mAbs were used as standard controls for the
ELISAs: T183 (IgM; Sigma Chemical Co.), 4G7 (IgG1; refer-
ence 19), Hy1.2 (IgG2a; reference 20), Pl9-10 (IgG2b), Pl9-11
(IgG3), Pl9-10 (anti-double stranded [ds]DNA; reference 21),
400t
 
m
 
23 (RF; reference 19), and LG4-1 (anti-chromatin; refer-
ence 22). 23.3 culture supernatant was used as the source of anti-
NP IgG2a for the rheumatoid factor ELISAs (19). Polyclonal
anti–mouse 
 
k
 
 conjugated to FITC (Southern Biotechnology As-
sociates, Inc.) was used in the immunofluorescence assays to de-
tect glomerular Ig deposition.
 
Cell Preparation and Flow Cytometry.
 
FACS
 
®
 
 analysis was con-
ducted as previously described (16).
 
ELISA.
 
For anti-Ig ELISA, Falcon 96-well, flat-bottomed
plates (Becton Dickinson) were coated overnight at 4
 
8
 
C with the
primary antibody (antiisotype). Plates were then blocked with 1%
BSA in PBS for 1 h at room temperature. Serum dilutions along
with the standard were allowed to incubate for 2 h. The second-
ary antibody (antiisotype conjugated to alkaline phosphatase;
Southern Biotechnology Associates, Inc.) was then incubated in
the plate for 1 h at room temperature.
For autoantibody ELISA, the assays were conducted in the
same manner as indicated above. However, the following were
used to coat the plates with autoantigen: poly-
 
l
 
-lysine and purified
calf thymus DNA (anti-dsDNA), NP/anti-NP IgG2a complexes
(RF), and purified calf thymus chromatin (antichromatin). The
secondary antibody was goat polyclonal anti–mouse 
 
k
 
 conjugated
to biotin, followed by streptavidin-alkaline phosphatase (South-
ern Biotechnology Associates, Inc.). The colorimetric data from
the pNPP substrate was quantified using Bio Kinetics Reader EL
340 (Bio-Tek Instruments). DeltaSoftIII software (BioMetallics,
Inc.) was used to analyze this data.
 
Tissue Preparation.
 
Kidneys were bisected and fixed in 10%
buffered formalin and embedded in paraffin, and sections were
stained with hematoxylin and eosin. For immunofluorescent evalu-
ation, kidney halves were lightly fixed in a 0.7% paraformaldehyde-
lysine-periodate solution overnight at 4
 
8
 
C. Then, each sample was
incubated in a 30% sucrose phosphate buffer at room temperature
for 
 
.
 
2 h and frozen in OCT compound (Tissue-Tek). 7-
 
m
 
m sec-
tions were cut using a Cryocut 1800 cryostat (Reichert-Jung) and
stained overnight with an anti–mouse 
 
k
 
 conjugated with FITC
(Southern Biotechnology Associates, Inc.). Fluorescence was visual-
ized using a Nikon Optiphot microscope (Nikon, Japan) at 200
 
3
 
or 400
 
3
 
 and was photographed with an exposure time of 5–6 s on
Elite ASA 400 film (Eastman Kodak Co.).
 
Renal Scoring.
 
The severity of nephritis and vasculitis was
graded based on a semiquantitative scale using the parameters de-
scribed in Table I of reference 23. In brief, a 0–4
 
1
 
 scale was used
for each compartment (glomerular, interstitial, and vascular) with
the pathology graded according to specified criteria as absent,
mild, moderate, or severe. For comparative purposes, all of the
tissue sections were scored by one observer (M.P.M.), who was
blinded to their origin, in three sessions for the unmanipulated
mice. A proportion of samples was reread a second time, with
generally excellent concordance (
 
,
 
1 point average difference). In
rare cases of disagreement, the sections were evaluated a third and
final time and the average of the scores was used.
 
Statistics.
 
Mortality curves were plotted using the Kaplan-
Meier method and examined for significance using the Mantel-
Cox logrank test. All other statistical tests used the nonparametric
Mann-Whitney U statistic. The statistical analyses were con- 
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ducted using StatView 4.5 (Abacus Software) for the Macintosh.
 
P 
 
, 
 
0.05 was considered significant.
 
Results
 
B Cells Are Restored in Tgic mIgM Mice.
 
Tgic mice with
the mIgM construct, which lacked the secreted exons,
were created as described in Materials and Methods. A dia-
gram of the Tg is shown in Fig. 1. Mice bearing the mIgM
Tg were backcrossed at least seven times to the B cell–defi-
cient J
 
H
 
D strain, placing the Tgs onto the autoimmune
MRL/
 
lpr
 
 background. This also established homozygosity
of the J
 
H
 
D mutation, which prevented the development of
B cells expressing endogenous Ig. As shown in Fig. 2, the
mIgM Tg restored B cell maturation. The percentages of B
cells in the Tg mice were comparable with those in wild-
type animals (average spleen percentage: B cell–intact 
 
2
 
15 
 
6 
 
7%, mIgM – 16 
 
6 
 
8).
 
mIgM Mice Have Greater Splenomegaly than J
 
H
 
D Mice.
 
J
 
H
 
D mice at 4–6 mo of age have reduced lymphoid organ
weights and cell numbers compared with B cell–intact ani-
mals (13, 16). Table I lists the cell numbers and organ
weights of the mIgM Tgic animals along with age-matched
B cell–intact and B cell–deficient MRL/
 
lpr
 
 mice. Splenic
weight and cell number were greater in mIgM mice than
in B cell–deficient animals (weight: 2.5-fold increase,
 
 P 
 
,
 
0.02; cell number: 2.2-fold increase,
 
 P 
 
, 
 
0.002). Since B
cells generally comprise only 15–20% of splenocytes in
older MRL/
 
lpr
 
 mice, this 2.2-fold difference in cell num-
ber cannot be accounted for simply by B cells per se. Most
of the increased cell number is attributable, instead, to T
cells, consistent with our previous reports on the effect of B
cells on T cell activation and expansion. Although signifi-
cantly greater than J
 
H
 
D/
 
lpr
 
 mice, splenomegaly in the
mIgM Tgics was decreased when compared with control
MRL/
 
lpr
 
 mice. Similarly, in the lymph nodes restoration of
B cells in the Tgic mice had no effect on weight and cell
number. The phenotype of partial restoration of T cell ac-
cumulation mediated by the Tgic mice most likely reflects
the restricted repertoire enforced by a single V
 
H
 
 in the Tg.
A partial or reduced disease phenotype has been found in
several other conventional Ig or TCR Tgic strains associ-
ated with the partial repertoire restriction imposed by al-
lelic exclusion by the Tgs (24, 25).
 
Spontaneous T Cell Activation in mIgM Mice Occurs in the
Absence of Circulating Ig.
 
The majority of T cells in MRL/
 
lpr
 
 mice have an activated/memory phenotype (16, 26).
However, in B cell–deficient MRL/lpr animals, the per-
centage of naive cells is increased, whereas the percentage
of memory T cells is decreased (16). Furthermore, B cells
are required for the accumulation of most memory T cells
since there are 5–10 times as many memory T cells in B
cell–intact mice compared with B cell–deficient mice. In
principle, B cells could be exerting this effect on memory
T cell development either directly (e.g., via presentation of
[auto]antigens) or indirectly (e.g., via autoantibody-medi-
ated inflammation causing the release of autoantigens).
To distinguish between these possibilities and to deter-
mine the mechanism by which B cells promote spontane-
ous T cell activation, we analyzed CD41 T cells from the
spleens of mIgM mice for expression of CD44 and CD62L
(Fig. 3). The T cell activation profiles of mIgM animals re-
sembled B cell–intact mice rather than B cell–deficient
mice. When compared with JHD animals, the percentages
of memory cells (CD44high, CD62Llow) were significantly
greater (1.6-fold increase, P , 0.0005) in mIgM mice (Fig.
3 D). Furthermore, percentages of naive cells (CD44low,
Figure 1. Tg schematic. The mIgM heavy chain Tg is depicted. The
DNA directing secretion (ms) and the transcription termination site (pAs)
have been deleted. VH186.2 is the rearranged heavy chain V(D)J segment.
E indicates the heavy chain intronic enhancer. Much of the switch region
has been deleted; a small region of residual switch region is indicated.
Figure 2. The Tg restores splenic B cells in JHD mice. Spleen cells
from JHD (A), mIgM (B), and MRL/lpr (C) mice were analyzed via flow
cytometry. Live (propidium iodide–negative) cells were analyzed for
CD19 (PE) and B220 (FITC) expression. B cells are B2201/CD191 (up-
per right quadrant). Percentages of B cells among live splenocytes are
shown. In MRL/lpr mice, B2201/CD192 cells are T cells.
Table I. Lymphoid Organ Weight and Total Cell Numbers of 
mIgM, MRL/lpr, and JHD Mice
Genotype
Spleen Lymph node
Weight Cell No. Weight Cell No.
mg 3106 mg 3106
mIgM 366 6 107* 181 6 43* 11 6 54  6 3
MRL/lpr 696 6 358* 224 6 162* 175 6 150* 59 6 67*
JHD 148 6 80 82 6 72 32 6 37 12 6 17
Splenic and inguinal lymph node organ weights and total cell numbers
were obtained from mIgM, MRL/lpr (B cell–intact), and JHD (B cell–
deficient) mice. Averages and one standard deviation were calculated
from samples consisting of 6–8-mo-old animals. Sample sizes for spleen
and lymph nodes are as follows: mIgM weight and cell number (n 5 6),
MRL/lpr weight and cell number (n 5 25), JHD weight (n 5 9), and
JHD cell number (n 5 8).
*P , 0.05 for comparisons to B cell–deficient JHD mice.1642 B Cell–dependent, Antibody-independent Murine Lupus
CD62Lhigh) were reduced by 90% (P , 0.002). The num-
ber of memory CD41 T cells in the mIgM mice was greater
(5.5-fold increase, P , 0.003) than that of B cell–deficient
animals and was similar to the B cell–intact, control MRL/
lpr mice (Fig. 3 E). As in the spleen, the percentage of naive
cells in the lymph nodes was decreased and the percentage
of memory cells was increased in mIgM Tgic mice com-
pared with B cell–deficient animals (data not shown).
However, there was no statistical difference in memory
CD41 cell number since lymph nodes were not generally
enlarged in the mIgM mice. For CD81 T cells, a similar
pattern of naive cell reduction and memory cell augmenta-
tion was observed (data not shown). Since the accumula-
tion of memory and activated T cells proceeded efficiently
in the absence of secreted antibody (see below) in the
mIgM mice, we conclude that B cells directly promote T
cell activation and accumulation, rather than indirectly via
antibody-mediated tissue damage.
mIgM Mice Develop Renal Lesions in the Absence of Circulat-
ing Ig. MRL/lpr mice characteristically develop spontane-
ous nephritis (Fig. 4, E and F), whereas B cell–deficient
JHD mice do not (Fig. 4, G and H) (13). mIgM mice, on
the other hand, have significant cellular infiltrates in the re-
nal interstitium and around the vessels, despite the inhibi-
tion of secreted Ig (Fig. 4, A–D). These infiltrates were
predominantly composed of T cells (data not shown).
Renal disease in the glomeruli, interstitium, and vessels
was scored blindly to assess severity (Fig. 5, A–C). IN and
vasculitis scores of the mIgM mice were greater than those
of the JHD animals (interstitium, P , 0.03; vessels, P ,
0.03) and comparable to those of the MRL/lpr mice. There
were no statistically significant differences in glomerular
scores between the JHD and mIgM strains, both of which
were lower than MRL/lpr mice (P , 0.02). Nevertheless,
focal lesions that resembled glomerular atrophy were ob-
served in some glomeruli of the mIgM mice (Fig. 4, A and
C), whereas these lesions were never observed in the JHD
strain (Fig. 4, G and H). This picture is different than the
typical proliferative GN picture seen in mild to moderate
MRL/lpr disease and may reflect a previously unappreci-
ated antibody-independent mode of glomerular disease
perhaps related to adjacent interstitial or vascular disease.
mIgM Mice Have Greater Mortality than JHD Mice. In our
colony, 50% mortality for B cell–intact MRL/lpr mice oc-
curred at 32 wk (n 5 203) (Fig. 5 D). The JHD strain, with
markedly reduced nephritis, vasculitis, and T cell activa-
tion, had a significantly greater life span (n 5 267, P ,
0.0001). The mortality of mIgM mice (50% at 56 weeks, n 5
71) was accelerated when compared with the JHD mice (P ,
0.0001), demonstrating that the restoration of B cells in the
absence of circulating, soluble autoantibody has a direct and
relevant effect on disease expression. However, in keeping
with the fact that restoration of B cells with a restricted
repertoire leads to milder nephritis and somewhat less T
cell activation than in wild-type MRL/lpr animals, mIgM
mice also had prolonged survival compared with the con-
trol MRL/lpr strain (P , 0.0007).
mIgM Mice Do Not Have Significant Serum Antibody. To
confirm the absence of secreted antibody in the mIgM
strain, serum Ig and autoantibody levels were measured
(Fig. 6). Some animals had no detectable Ig as expected
(baseline dots in Fig. 6). However, others had trace quanti-
ties of some Ig isotypes; these concentrations were 100–
1,000 times lower than MRL/lpr controls. Notably, there
Figure 3. Spontaneous splenic CD41
T cell activation is restored by the
mIgM Tg. Three-color FACS® analysis
was conducted on splenocytes. Repre-
sentative FACS® contour plots are
shown for JHD (A), MRL/lpr (B), and
mIgM (C) mice. CD4high gated cells
were analyzed for CD44 (FITC) and
CD62L (PE) expression. Percentages of
total CD41 T cells (D) were obtained
for the naive (CD44lowCD62Lhigh), acti-
vated (CD44highCD62Lhigh), and mem-
ory (CD44highCD62Llow) subsets as de-
picted in parts A–C. Cell numbers (E)
were calculated by multiplying total cell
percentages of each activation subset by
the total spleen cell number for each
mouse. Columns show the averages of
percentages (D) or cell numbers (E) of a
cohort of mice. Error bars represent one
standard deviation. Sample sizes for cell
percentages are: JHD (n 5 17), MRL/lpr
(n 5 26), mIgM (n 5 6) mice. Sample
sizes for cell numbers are: JHD (n 5 9),
MRL/lpr (n 5 25), mIgM (n 5 5). All
mice were 24–32 wk of age. Asterisks
indicate significant differences of P ,
0.05 with the B cell–deficient group, as
determined by the two-tailed Mann-
Whitney U test.1643 Chan et al.
were mIgM animals that did not have any detectable serum
Ig, yet developed renal disease. Finally, there was no signif-
icant total anti-dsDNA, RF, or antichromatin detected in
the serum for most of the mIgM mice (Fig. 6 B).
Ig Deposition Is Not Detected in the Kidneys of mIgM Mice.
Using immunofluorescence, we examined the kidneys of
two mIgM mice that had detectable circulating Ig. In both,
there were no observable Ig deposits in the glomeruli, in-
terstitium, or vessels, consistent with the low to absent lev-
els of serum Ig and autoantibodies. These mIgM kidneys
were indistinguishable in this regard from kidneys of the B
cell–deficient, negative controls, whereas MRL/lpr mice
showed intense staining, as expected (Fig. 7).
Discussion
SLE is a complex disease that may have multiple pathogenic
manifestations. In addition to the classic GN, vasculitis, IN,
arthritis, and skin disease are often seen. The key finding of
this work is that in the absence of circulating Ig and renal an-
tibody deposition, the mIgM strain developed IN, vasculitis,
and focal glomerular atrophy. Thus, these studies demonstrate
for the first time an antibody-independent mechanism for
renal and vascular disease in a murine model of SLE. Disease
promoted by B cells in the absence of Ab is biologically rele-
vant in that IN, vasculitis, and, importantly, mortality were all
enhanced by B cells alone. To the extent that these results
are generalizable to other murine models and to human
SLE, the data suggest a wider view of lupus pathogenesis,
which is generally thought to be solely antibody mediated (1).
Renal cellular infiltrates in MRL/lpr mice, which are not
observed in the JHD strain, contain significant numbers of T
cells (Chan, O.T.M., and M.J. Shlomchik, unpublished ob-
servation, and references 6, 27). These cells are restored in
mIgM mice (Fig. 4 and immunocytochemistry data not
shown). It is important to emphasize that interstitial disease
and vasculitis are prominent features in diseased kidneys of
many SLE patients (7, 9, 12). Indeed, interstitial injury may
correlate best with overall outcome. Moreover, cellular infil-
tration is a prominent feature in other SLE manifestations,
such as some skin lesions and sialoadenitis (10, 28). It is worth
noting that cellular infiltration in the MRL/lpr model is
not due to the Faslpr mutation since Fas-intact MRL/MpJ-
1Fas-lpr/1Fas-lpr mice also develop cellular infiltrates (references
3 and 5, and Chan, O.T.M., unpublished data).
Although overall statistical analysis of blind readings in a
system that emphasized generalized disease did not show a
difference in glomerular disease, this masks the fact that focal
glomerular lesions were seen in mIgM mice (Fig. 4). Focal
glomerular lesions have never been noted in JHD mice (13).
The nature of these lesions has not yet been defined; they
could be due to adjacent vascular damage, periglomerular in-
filtrates, and/or local release of toxic cytokines (8, 29). How-
ever, it seems that in the absence of marked glomerular dis-
ease, an antibody-mediated component is missing from the
mIgM mice, as might have been predicted. The relationship
of IN and GN has been controversial and the subject of spec-
ulation in the literature (30); but, until now, linkage could
not be addressed in any experimental way in either humans
or murine models. The present data show that IN and vascu-
litis can proceed without severe GN, but that some elements
of GN might be exacerbated or even caused by surrounding
cellular infiltrates as suggested by focal glomerular necrosis
observed. In fact, several recent studies of experimental GN
models that were thought to be solely antibody mediated
have now demonstrated an important role for T cells (31–34).
From all these studies, one could propose that there is synergy
and cooperation among B and T cells to mediate a variety of
pathogenic outcomes and that T cells do play a direct role in
mediating disease that was previously thought to be only anti-
body dependent.
The mIgM Tgic mice accumulated memory T cells in
their spleens at levels similar to that of wild-type animals, in
contrast to B cell–deficient mice. Thus, T cell activation is
antibody-independent, but exactly how B cells promote T
cell activation and cellular infiltration into tissues such as
Figure 4. Lupus nephritis occurs in the absence of circulating Ig. Kidneys
were fixed in formalin, and sections were stained with hematoxylin and
eosin: (A) 23 wk mIgM, (B) 30 wk mIgM, (C and D) 42 wk mIgM, (E) 31
wk MRL/lpr, (F) 30 wk MRL/lpr, and (G and H) 45 wk JHD. Cellular in-
terstitial and perivascular infiltrates are observed in mIgM (A–D) and
MRL/lpr (E and F), but not in JHD mice, even up to 45 wk of age (G and
H). Black arrows point to glomerular lesions in the mIgM mice (A and C).1644 B Cell–dependent, Antibody-independent Murine Lupus
kidney and vessels is not completely clear. However, it is
likely that B cells primarily act as autoantigen-presenting
cells for the amplification of autoreactive T cells. In this
scenario, autoreactive T cells may initially be activated by
other APCs, such as dendritic cells; however, as B cell au-
toimmunity progresses and expanded clones of self-reactive
B cells accumulate (35, 36), these cells become increasingly
important APCs for T cells (37–41). B cells are known to
be extraordinarily efficient APCs for antigens that can bind
to their surface Ig (42–44). Indeed, B cells that accumulate
in MRL/lpr mice chiefly have specificity for self-IgG (RFs)
or DNA/histone (36). Such B cells bind particles (either
immune complexes or nucleosomes) that are likely to con-
tain multiple proteins, which could stimulate self-reactive
T cells. Thus, these B cells are well suited to obtain T cell
help. As certain autoreactive B cells expand and dominate
the B cell repertoire, their relative importance in promot-
ing disease via T cell activation (possibly including breaking
peripheral T cell tolerance) (45, 46) and autoantibody se-
cretion would escalate. This might represent an element of
a positive feedback circuit that leads to fulminant disease.
Mamula, Janeway, and colleagues first suggested that B
cells might be important autoantigen-presenting cells and
might promote the breakdown of peripheral T cell toler-
ance (45–47). Using a cross-immunization scheme in nor-
mal mice, they were able to elicit autoreactive T cells in a
fashion that was likely to be B cell dependent. They also
suggested that this might be a mechanism for epitope
spreading, a common phenomenon in both lupus and or-
gan-specific autoimmunity. These studies were conducted
Figure 5. Kidney disease scores and
mortality in MRL/lpr mice. Kidney
samples were examined via light micros-
copy and scored blindly for disease on a
semiquantitative scale from 0 (normal)
to 4 (maximum). Scores for the glomer-
uli (A), interstitium (B), and vessels (C)
are shown above. Each point represents
an individual animal. Black horizontal
bars indicate the median score. All ani-
mals were 24–30 wk of age. Compari-
sons to JHD mice were conducted, and
statistical significance is indicated in each
graph. Sample sizes for the mortality
graph (D) are: MRL/lpr (n 5 203), JHD
(n 5 267), and mIgM (n 5 71). The
JHD mice had greater survival than either
MRL/lpr (P , 0.0001) or mIgM (P ,
0.0001) mice. Survival curves were gen-
erated as described in Materials and Meth-
ods using the Kaplan-Meier method and
examined for statistical significance using
the Mantel-Cox logrank tests.
Figure 6. Serum Ig levels. Sera were
obtained from mIgM, MRL/lpr, and
JHD mice. Ig levels as determined by
ELISA for isotypes IgM, IgG1, and
IgG2a are shown on the logarithmic y
axis in A. Anti-dsDNA, anti-IgG2a
rheumatoid factor, and antichromatin Ig
are shown in B. Each point represents
one mouse. Horizontal bars indicate the
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in normal mice via immunization with heterologous pro-
teins in Freund’s adjuvant. Our work now lends support to
the idea that these mechanisms are actually operating in
spontaneously autoimmune animals.
Although we favor a role for B cells as APCs, we cannot
formally rule out that B cells are also acting as producers of
cytokines that promote T cell activation or pathology. B
cells are known to produce cytokines under certain cir-
cumstances (48–51). However, since B cells are not consid-
ered major producers of cytokines, it is difficult to envision
B cells as supplying rate-limiting quantities of cytokines,
particularly in a scenario in which there is massive T cell
activation. In addition, immunohistochemical analyses re-
vealed few B cells in the proximity of the renal infiltrates of
MRL/lpr mice (data not shown), making it very unlikely
that B cells are the source of cytokines responsible for di-
rect parenchymal injury.
Although IN and vasculitis were marked in mIgM mice
compared with their B cell–deficient MRL/lpr counter-
parts, the median renal disease scores of the mIgM mice
were not as high as those of the control MRL/lpr mice.
Similarly, mIgM mice had substantially accelerated mortal-
ity compared with B cell–deficient MRL/lpr mice; but
these Tgic mice had delayed mortality when compared
with the wild-type. The lack of circulating autoantibody
could certainly contribute to milder disease. Particularly for
IN and vasculitis, it is likely that milder disease in mIgM
mice is also due to a reduced Ig repertoire resulting from
the fixed heavy chain Tg. It is possible that this restriction
limited the generation of autoreactive B cells in the Tgic
animals, thereby inhibiting the full potential of the B cell
compartment to recognize self-antigens, activate them, and
present these autoantigens to T cells. We predict that dis-
ease would have been more severe had a full Ig repertoire
been expressed, but thus far the technology to produce
such a mouse is not readily at hand.
The importance in SLE of cell-mediated autoimmune
pathogenesis revealed by our studies is reminiscent of
present views of organ-specific autoimmune diseases such
as diabetes. It is intriguing that B cell deletion also inhibited
diabetes in the nonobese diabetic (NOD) mouse (52–54).
This result was interpreted as due to lack of APC function,
a point that was not actually proven but could potentially
be demonstrated directly using our Tgs on the NOD back-
ground. In any case, the similarities suggest that organ-speci-
fic and systemic autoimmunity may not need to be distin-
guished as much on the basis of pathogenic mechanism, but
rather in extent of autoimmune targeting. Our studies fur-
ther support the rationale for directly targeting B cells in
the therapy of SLE (13, 16) and, by extension of this logic,
to other autoimmune diseases.
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